Brett Schafer

[Brett Schafer @BrettSchafer23]

@LouBasenese My heart hurts with you. Just know, he may have lost his body in this realm, but his spirit walks with you everyday; probably more than ever! There’s no doubt he’s proud of you. Hang in there brother. 🙏❤️

[Brett Schafer @BrettSchafer23]

@MakisMedicine How do I get your help? My mom has reoccurrence Ovarian cancer. We’ve emailed and I’ve DM’d.

Thx,

Brett

[Brett Schafer @BrettSchafer23]

@LouBasenese I’ve been appreciating it the last couple of years. About to finish off the full appreciation of this year as well. 💪

[Brett Schafer @BrettSchafer23]

@LouBasenese Heart is with you brother 🙏

[Brett Schafer @BrettSchafer23]

@mikealfred Plz open DM, thx.

[Brett Schafer @BrettSchafer23]

Congratulations to Gain Therapeutics on receiving FDA clearance for GT-02287 to advance into Phase 2.

I’ve always believed the best investments are in companies that have the potential to make a meaningful difference in people’s lives. Gain Therapeutics is pursuing exactly that.

GT-02287 has the potential to become the first disease-modifying treatment for Parkinson’s disease. Today, approved therapies primarily help manage symptoms. If successful, GT-02287 could change the course of the disease and bring hope to millions of patients and their families.

To me, this is the ultimate win-win:
• Patients and families win with the possibility of a treatment that potentially stops and slows disease progression.
• Investors win by supporting innovation that has the potential to create tremendous value while improving lives.

Congratulations to the entire Gain Therapeutics team on this important milestone. Wishing you success in Phase 2 and beyond.

Here’s to another WIN/WIN. $GANX